Skip to main
HUMA
HUMA logo

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 86%
Buy 14%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte Inc. is advancing its manufacturing capabilities and expanding hospital access, which are anticipated to be critical factors in driving commercial uptake and revenue growth through 2026. The company's positioning in trauma vascular repair enhances its credibility in both military and civilian markets, reinforcing its competitive standing. Additionally, the validation of the durable performance of its biologic conduit in complex clinical situations adds to the optimism surrounding its innovative biotechnology platform and diverse pipeline.

Bears say

The financial analysis indicates that Humacyte Inc faces significant challenges in achieving commercial viability for its innovative biotechnology platform, as the company continues to report substantial operating losses and negative cash flow. Additionally, the lengthy and costly regulatory approval process for its diverse pipeline, which includes products for vascular trauma and organ systems, creates uncertainty around timelines for revenue generation and market entry. Furthermore, competitive pressures within the biotechnology sector and the necessity for continuous funding could hinder Humacyte's growth potential, resulting in a negative outlook for the stock.

Humacyte (HUMA) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 86% of analysts recommend a Strong Buy, 14% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Humacyte (HUMA) has a Strong Buy consensus rating as of Oct 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.43, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.43, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.